EST 0469B--comparison of high- and low-dose cyclophosphamide in human lung cancer.
A controlled trial of high-intermittent vs low-chronic dose cyclophosphamide in human lung cancer failed to show the benefits reported in noncontrolled trials. There were no differences in toxicity observed.